CN109153641B - 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途 - Google Patents

伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途 Download PDF

Info

Publication number
CN109153641B
CN109153641B CN201780029003.XA CN201780029003A CN109153641B CN 109153641 B CN109153641 B CN 109153641B CN 201780029003 A CN201780029003 A CN 201780029003A CN 109153641 B CN109153641 B CN 109153641B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
group
rgd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780029003.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109153641A (zh
Inventor
陈小元
欧里特·雅各布森·韦斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CN109153641A publication Critical patent/CN109153641A/zh
Application granted granted Critical
Publication of CN109153641B publication Critical patent/CN109153641B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B29/00—Monoazo dyes prepared by diazotising and coupling
    • C09B29/24—Monoazo dyes prepared by diazotising and coupling from coupling components containing both hydroxyl and amino directing groups
    • C09B29/28—Amino naphthols
    • C09B29/30—Amino naphtholsulfonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780029003.XA 2016-05-09 2017-05-09 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途 Active CN109153641B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333427P 2016-05-09 2016-05-09
US62/333,427 2016-05-09
PCT/US2017/031696 WO2017196806A1 (en) 2016-05-09 2017-05-09 Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents

Publications (2)

Publication Number Publication Date
CN109153641A CN109153641A (zh) 2019-01-04
CN109153641B true CN109153641B (zh) 2022-10-18

Family

ID=60267260

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780029003.XA Active CN109153641B (zh) 2016-05-09 2017-05-09 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途

Country Status (6)

Country Link
US (1) US10696631B2 (enExample)
EP (1) EP3455206B1 (enExample)
JP (1) JP6946342B2 (enExample)
CN (1) CN109153641B (enExample)
SG (1) SG11201809982RA (enExample)
WO (1) WO2017196806A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016209795A1 (en) 2015-06-22 2016-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics
US10981866B2 (en) 2017-10-03 2021-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents
CA3090812A1 (en) * 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
TWI745616B (zh) * 2018-09-10 2021-11-11 行政院原子能委員會核能研究所 放射線標誌長效型靶向性胜肽藥物及其生產方法
CN109485642A (zh) * 2018-11-21 2019-03-19 希施生物科技（上海）有限公司 一种制备伊文氏蓝衍生物的方法
CN113366064A (zh) * 2019-01-30 2021-09-07 美国政府健康及人类服务部 二价伊凡斯蓝染料衍生物的缀合物和应用方法
US12357712B2 (en) * 2019-05-24 2025-07-15 Beijing Giluntide Pharmaceutical Co., Ltd. Targeted radiopharmaceutical for tumor and its use in the imaging-guided combination therapy of targeted radiotherapy and immunotherapy
CN115210240A (zh) * 2020-03-04 2022-10-18 日本医事物理股份有限公司 化合物及放射性标记化合物
CA3178858A1 (en) * 2020-05-06 2021-11-11 Cornell University Copper-containing theragnostic compounds and methods of use
CN114790193B (zh) * 2020-12-21 2024-05-10 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
CN114369084B (zh) * 2021-02-10 2023-02-03 烟台蓝纳成生物技术有限公司 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用
US11975079B2 (en) 2021-02-10 2024-05-07 Yantai Lannacheng Biotechnology Co., Ltd. Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof
CN113004371A (zh) * 2021-03-01 2021-06-22 上海蓝纳成生物技术有限公司 一种长循环半衰期的前列腺特异性膜抗原靶向化合物及其制备方法和应用
CN114796532A (zh) * 2022-04-20 2022-07-29 北京先通国际医药科技股份有限公司 放射性标记的伊文思蓝衍生物药物水溶液及其用途
EP4537851A1 (en) * 2022-06-10 2025-04-16 Peking University Trifunctional compound and use thereof
CN115433261B (zh) * 2022-11-07 2023-01-13 烟台蓝纳成生物技术有限公司 一种rgd二聚体化合物及其制备方法和应用
CN115583989B (zh) * 2022-12-09 2023-02-28 烟台蓝纳成生物技术有限公司 一种靶向sstr2的化合物及其制备方法和应用
CN115611779A (zh) * 2022-12-21 2023-01-17 北京先通国际医药科技股份有限公司 一种放射性药物前体的中间体的制备方法及其用途
CN115838393B (zh) * 2023-02-16 2023-05-05 烟台蓝纳成生物技术有限公司 用于fapi合成的中间体及其制备方法和应用
CN115850367B (zh) * 2023-03-02 2023-05-23 北京先通国际医药科技股份有限公司 Psma抑制剂的纯化方法及其用途
CN115947775B (zh) * 2023-03-13 2023-06-09 北京先通国际医药科技股份有限公司 一种制备化合物（i）的方法和化合物（i）及其用途
WO2024240251A1 (zh) * 2023-05-24 2024-11-28 北京昌平实验室 一种新的三功能化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101623504A (zh) * 2008-07-07 2010-01-13 中国人民解放军军事医学科学院放射与辐射医学研究所 伊文思蓝作为实体肿瘤着色剂的用途
CN103242255A (zh) * 2013-04-28 2013-08-14 厦门大学 伊文氏蓝配合物及其制备方法和应用
CN104650217A (zh) * 2015-01-26 2015-05-27 汇佳生物科技（上海）有限公司 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用
WO2016209795A1 (en) * 2015-06-22 2016-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4569875B2 (ja) 2003-02-27 2010-10-27 国立大学法人九州大学 Ｍｒｉ用造影剤
WO2006025304A1 (ja) 2004-08-30 2006-03-09 Kyushu University, National University Corporation 動脈硬化検知用ｍｒｉ造影剤
EP2187803A4 (en) * 2007-09-14 2011-05-11 Health Research Inc MULTIMODAL MEANS FOR THE IMAGING AND THERAPY OF TUMORS
JP5677096B2 (ja) * 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
US20160287730A1 (en) 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
US10981866B2 (en) 2017-10-03 2021-04-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents
CA3090812A1 (en) 2018-02-22 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101623504A (zh) * 2008-07-07 2010-01-13 中国人民解放军军事医学科学院放射与辐射医学研究所 伊文思蓝作为实体肿瘤着色剂的用途
CN103242255A (zh) * 2013-04-28 2013-08-14 厦门大学 伊文氏蓝配合物及其制备方法和应用
CN104650217A (zh) * 2015-01-26 2015-05-27 汇佳生物科技（上海）有限公司 伊文氏蓝或其衍生物修饰的Exendin-4及其制备方法和应用
WO2016209795A1 (en) * 2015-06-22 2016-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemical conjugates of evans blue derivatives and their use in the production of long-acting therapeutics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding;Haojun Chen et al.;《Theranostics》;20160101;第6卷(第2期);第243-253页 *
Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents;Haojun Chen et al.;《J Nucl Med》;20161122;第58卷;第590-597页 *
Stable Evans Blue Derived Exendin 4 Peptide for Type 2 Diabetes Treatment;Yi Liu et al.;《Bioconjugate Chem.》;20151207;第27卷;第54-58页 *

Also Published As

Publication number Publication date
JP2019519491A (ja) 2019-07-11
US20190084931A1 (en) 2019-03-21
SG11201809982RA (en) 2018-12-28
WO2017196806A1 (en) 2017-11-16
CN109153641A (zh) 2019-01-04
US10696631B2 (en) 2020-06-30
JP6946342B2 (ja) 2021-10-06
EP3455206A1 (en) 2019-03-20
EP3455206B1 (en) 2020-11-04
EP3455206A4 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
CN109153641B (zh) 伊文思蓝衍生物的化学偶联物及其作为放射治疗和成像剂的用途
US10981866B2 (en) Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents
CN111741751B (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
US10709790B2 (en) Chemical conjugates of Evans Blue derivatives and their use in the production of long-acting therapeutics
CN116940585A (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CN114341158A (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CN116940586A (zh) 包含成纤维细胞活化蛋白配体的化合物及其用途
CA2996330A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
Lindeman et al. FAP Radioligand Linker Optimization improves Tumor Dose and Tumor-to-healthy organ ratios in 4T1 syngeneic model
KR102902487B1 (ko) 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도
HK40026025A (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
HK40026025B (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
HK40029571B (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
HK40029571A (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant